From: Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria
Endolysin and/or derivative | Origin | The number of tested strains | The number of lysed strains | Host range | References |
---|---|---|---|---|---|
SAL200 | Staphylococcal phage SAP-1 | 425 | 425 | 100% | [61] |
Exebacase (CF-301 or PlySs2) | Prophage of Streptococcus suis | 477 | 365 | 77% | [62] |
P128 | CHAP domain (TAME phage K) + SH3b (lysostaphin) | 62 | 62 | 100% | [63] |
Staphefekt SA.100 | M23 endopeptidase (lysostaphin) + Amidase (Ply2638) + SH3b (Ply2638) | 11 | 10 | 91% | [64] |
XZ.700 | Staphefekt SA.100 deleted 44 amino acids region | 120 | 107 | 89% | [64] |
LysK | Staphylococcal phage K | 27 | 18 | 67% | [65] |
CHAPK (truncated LysK) | Staphylococcal phage K | 31 | 28 | 90% | [66] |
ClyF | CD domain (Ply187) + CBD domain (PlySs2) | 51 | 45 | 88% | [22] |
LysGH15 | Staphylococcal phage GH15 | 57 | 52 | 91% | [67] |
LysH5 | Staphylococcal phage PhiH5 | 90 | 77 | 86% | [68] |
Pal | Streptococcal phage Dp-1 | 25 | 19 | 76% | [16] |
Cpl-1 | Streptococcal phage Cp-1 | 27 | 22 | 81% | [69] |
PlyG | B. anthracis γ-phage | 27 | 16 | 59% | [24] |